← Research library

[Use of the Gepon immunomodulator for ulcerative colitis treatment].

Observational study · 2005

What was studied
36 patients with resistant distal ulcerative colitis
Main finding
In a 36-person uncontrolled report of resistant distal ulcerative colitis, 83.3% had clinical and endoscopic improvement after Gepon.

Within the treated cohort; no untreated response rate supplied

Reported findings and study design

In a 36-person uncontrolled report of resistant distal ulcerative colitis, 83.3% had clinical and endoscopic improvement after Gepon.

36 patients with resistant distal UC; adjunctive immunomodulation.

Results · Primary-publication indexed abstract; no full-text table appraisal
MeasureResultComparison, timing and statistics
Clinical and endoscopic amelioration83.3%Within the treated cohort; no untreated response rate supplied
Participants36

The percentage is an uncontrolled response proportion, not a placebo-adjusted remission rate. Long-term relapse and adverse-event rates are not quantified.

Source for these results ↗ · Reviewed 2026-11-01

Study limitations and source details

Study limitations

  • No concurrent comparator is described; the reported response proportion is not an effect versus placebo or standard care.
  • Full methods, reporting completeness and independent replication remain to be appraised.

Source details

Original journal report

Primary citation and indexed abstract reviewed through Europe PMC. Full article not appraised.

Abstract reviewed

Sources checked

Citation

Uncontrolled human reportEnglish abstract

Malakhova NS, Pichugin AV, Khalif IL, Ataullakhanov RI. [Use of the Gepon immunomodulator for ulcerative colitis treatment]. Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology · PMID 15991847

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards